Apollo Hospitals has completed a Multi-Week Breakout above its prior consolidation zone. Trading well above its 20-Week EMA (₹8,928.30) and all major daily moving averages, the stock is demonstrating strong structural momentum toward fresh highs.
Key Trade Parameters
Entry Range: Current Levels / Re-test zone at ₹8,925 – ₹8,957
Stop Loss: ₹8,591.50 (placed strictly below the recent swing consolidation base)
Target 1: ₹9,323.50 (Initial upside extension)
Target 2: ₹9,738.50 (1-year analyst price target / macro extension)
Risk-to-Reward (R:R) Breakdown
Risk Per Share: ~₹365.50 (from an entry near ₹8,957 down to SL of ₹8,591.50)
Reward to Target 1: ~₹366.50 (R:R Ratio ~ 1:1)
Reward to Target 2: ~₹781.50 (R:R Ratio ~ 1:2.14)
Execution Note: To optimize risk management, trail stop loss to breakeven or to the 20-Week EMA once Target 1 (₹9,323.50) is achieved, allowing the remaining position to ride toward Target 2
Disclaimer: aliceblueonline.com/legal-documentation/disclaimer
Key Trade Parameters
Entry Range: Current Levels / Re-test zone at ₹8,925 – ₹8,957
Stop Loss: ₹8,591.50 (placed strictly below the recent swing consolidation base)
Target 1: ₹9,323.50 (Initial upside extension)
Target 2: ₹9,738.50 (1-year analyst price target / macro extension)
Risk-to-Reward (R:R) Breakdown
Risk Per Share: ~₹365.50 (from an entry near ₹8,957 down to SL of ₹8,591.50)
Reward to Target 1: ~₹366.50 (R:R Ratio ~ 1:1)
Reward to Target 2: ~₹781.50 (R:R Ratio ~ 1:2.14)
Execution Note: To optimize risk management, trail stop loss to breakeven or to the 20-Week EMA once Target 1 (₹9,323.50) is achieved, allowing the remaining position to ride toward Target 2
Disclaimer: aliceblueonline.com/legal-documentation/disclaimer
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.